| Headache |
1 |
1 |
| Migraine |
0 |
0.65 |
| COVID-19 |
0 |
0.99 |
| Connecticut |
0 |
0.47 |
| Brain |
0 |
0.35 |
| Blood-Brain Barrier |
0 |
0.34 |
| COVID-19 Vaccine |
0 |
0.34 |
| CNS Infection |
0 |
0.25 |
| Myalgia |
0 |
0.25 |
| Central Nervous System |
0 |
0.23 |
| Fatigue |
0 |
0.23 |
| Pain |
0 |
0.23 |
| Receptors |
0 |
0.23 |
| Otolaryngology |
0 |
0.13 |
| Adverse Effects |
0 |
0.12 |
| Ageusia |
0 |
0.12 |
| Anosmia |
0 |
0.12 |
| Blood |
0 |
0.12 |
| Board Certification |
0 |
0.12 |
| C-Reactive Protein (CRP) |
0 |
0.12 |
| California |
0 |
0.12 |
| Clinical Research |
0 |
0.12 |
| Cytokines |
0 |
0.12 |
| Dehydration |
0 |
0.12 |
| Dizziness |
0 |
0.12 |
| Epithelium |
0 |
0.12 |
| Fever |
0 |
0.12 |
| Health Care Facilities, Manpower, and Services |
0 |
0.12 |
| Hypoxia |
0 |
0.12 |
| Inpatient Care |
0 |
0.12 |
| Insomnia |
0 |
0.12 |
| Ischemic Stroke |
0 |
0.12 |
| Lumbar Puncture |
0 |
0.12 |
| Lung |
0 |
0.12 |
| Meningitis |
0 |
0.12 |
| Meta-Analysis |
0 |
0.12 |
| Metabolism |
0 |
0.12 |
| Nerve |
0 |
0.12 |
| Polymerase Chain Reaction |
0 |
0.12 |
| Preventive Screening |
0 |
0.12 |
| Seizure |
0 |
0.12 |
| Severe Acute Respiratory Syndrome |
0 |
0.12 |
| Sinus |
0 |
0.12 |
| Thrombosis |
0 |
0.12 |
| Viral Infection |
0 |
0.12 |
| Cerebrovascular Accident |
0 |
0.09 |
| Thromboembolism |
0 |
0.08 |
| Pain Management |
0 |
0.07 |
| Patient Safety |
0 |
0.06 |
| Meningococcal Disease |
0 |
0.05 |
| Vaccines |
0 |
0.04 |
| Acute Respiratory Distress Syndrome |
0 |
0.02 |
| Dentistry and Oral Health |
0 |
0.02 |
| Sleep Disorders |
0 |
0.02 |